Literature DB >> 4051730

Complications of pelvic exenteration.

J G Jakowatz, D Porudominsky, D U Riihimaki, M Kemeny, W A Kokal, P S Braly, J J Terz, J D Beatty.   

Abstract

This report is based on a retrospective review of 104 patients who had undergone pelvic exenteration for advanced malignancy over a 29-year period (1956 to 1984, inclusive). Fifty-one patients (49%) developed major complications of the operative field involving the gastrointestinal tract (fistula or obstruction), the urinary tract (fistula, infection, or obstruction), or the wound (abscess, dehiscence/necrosis, or hemorrhage). No association was identified between the complication rate and organ of primary disease, extent of disease, tumor histology, or extent of resection. Patients receiving pelvic radiotherapy prior to exenteration had a much higher complication rate (39/58, 67%) than patients having had no radiotherapy (12/46, 26%). Reconstruction of the irradiated pelvis after exenteration by omental flap, colonic advancement, and/or myocutaneous flaps decreased the complication rate from 82% (27/33) to 48% (12/25). The operative mortality of pelvic exenteration was 2.9% and the actuarial five-year survival rate was 27%.

Entities:  

Mesh:

Year:  1985        PMID: 4051730     DOI: 10.1001/archsurg.1985.01390350043009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  12 in total

1.  Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.

Authors:  H Horie; H Kashiwagi; F Konishi; K Furuta; A Ozawa; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era.

Authors:  Paul J Speicher; Ryan S Turley; Jason L Sloane; Christopher R Mantyh; John Migaly
Journal:  J Gastrointest Surg       Date:  2013-11-08       Impact factor: 3.452

3.  Omentoplasty in the prevention of anastomotic leakage after colorectal resection: a meta-analysis.

Authors:  Xiang-Yong Hao; Ke-Hu Yang; Tian-Kang Guo; Bin Ma; Jin-Hui Tian; Hong-Ling Li
Journal:  Int J Colorectal Dis       Date:  2008-09-02       Impact factor: 2.571

4.  Omentoplasty in the prevention of anastomotic leakage after colonic or rectal resection: a prospective randomized study in 712 patients. French Associations for Surgical Research.

Authors:  F Merad; J M Hay; A Fingerhut; Y Flamant; J M Molkhou; Y Laborde
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

Review 5.  Is total pelvic exenteration reasonable primary treatment for rectal carcinoma?

Authors:  L F Williams; C B Huddleston; J L Sawyers; J R Potts; K W Sharp; S W McDougal
Journal:  Ann Surg       Date:  1988-06       Impact factor: 12.969

6.  [Microsurgical reconstruction of the pelvic floor after pelvic exenteration. Reduced morbidity and improved quality of life by an interdisciplinary concept].

Authors:  N M Stechl; S Baumeister; K Grimm; T W Kraus; H Bockhorn; K E Exner
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

7.  Morbidity and mortality after pelvic exenteration for colorectal adenocarcinoma.

Authors:  G H Hafner; L Herrera; N J Petrelli
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

8.  Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case.

Authors:  S Fujimoto; M Takahashi; K Kobayashi; M Kure; H Masaoka; H Ohkubo; S Isaka; J Shimazaki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Retrospective review of pelvic malignancies undergoing total pelvic exenteration.

Authors:  Maureen P Kuhrt; Ravi J Chokshi; David Arrese; Edward W Martin
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

10.  Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution.

Authors:  Horacio N López-Basave; Flavia Morales-Vásquez; Angel Herrera-Gómez; Alejandro Padilla Rosciano; Abelardo Meneses-García; Juan M Ruiz-Molina
Journal:  Cancer Manag Res       Date:  2012-10-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.